Advisory Board and Editors Immunology
Angela Rösen-Wolff
Study of Medicine at the Ruprecht-Karls-Universiy in Heidelberg, Germany; Habilitation in Experimental Virology. Head of Clinical Research at the Department of Pediatrics, University Hospital Carl Gustav Carus at TU Dresden, Germany, since 1995. Speaker of Clinical Research Unit 249 "Defects of the Innate Immune System in Autoinflammation and Autoimmunity" since 2010
David Schrama
Research focus on tumorimmunology and tumorbiology of skin cancer especially melanoma and merkel cell carcinoma. PhD and Post-Doc at medical university hospital Wuerzburg. Now Associate Professor at Medical University Graz, Austria.
Martina Schroeder
Dr Martina Schroeder is a Lecturer and Head of the Host-Pathogen Interaction Lab at Maynooth University. Her research addresses viral recognition, innate immune signaling pathways, and the roles of DEAD-box proteins in immunity. Previously Dr Schroeder conducted postdoctoral research with Prof. Andrew Bowie at Trinity College Dublin. In 2007, she was awarded a postdoctoral career development fellowship by the Irish HRB. She completed her PhD at the Charité University Hospital in Berlin in 2003.
Florian Sennlaub
Senior staff researcher at the French National Institute of Health Research (Inserm). Head of the therapeutics department and director of the research team "Inflammation, degeneration and vascular remodelling in retinal disease" at the Vision Institute in Paris. Recipient of a ERC starting grant.
Huashan Shi
Professor Shi Huashan is an Associate Professor at Sichuan University. His expertise is in the molecular biology of tumours and tumour transcriptomics. He is currently engaged in clinical and basic translational research, including tumour microenvironment and novel immunotherapeutic modalities, and research on the mechanisms and medical applications related to tumour cell vaccines.
Arif J Siddiqui
Dr. Arif Jamal Siddiqui is an Associate Professor and Principal Investigator at the Department of Biology, College of Science, University of Hail, Saudi Arabia. He received his PhD from CSIR-Central Drug Research Institute, Lucknow, India in 2015. From 2015 to 2018, he worked as a Post-Doctoral Fellow at Texas Tech University Health Sciences Center, Lubbock, Texas, United States of America.
He has more than 8 years of experience in research, teaching and administration. In his professional work, he has received research grants as a Principal Investigator from various renowned organizations. He has successfully published more than 100 publications in internationally recognized peer-reviewed prestigious journals, published several book chapters for internationally renowned publishers and presented many articles and posters in various conferences/workshops worldwide. He has published numerous papers in the fields of parasitology, immunology, herbal medicine, vaccine development, drug discovery and natural products with a specialization in anti-parasitic, antiviral, anticancer and antibacterial agents. Furthermore, he is a member of The Indian Science Congress Association, India and the Annals of Parasitology, Poland. He has reviewed more than 250 manuscripts and he also currently holds various editorial positions (Academic, Associate, Guest and Review Editor) in various reputable journals and has edited more than 150 manuscripts.
Linsheng Song
Professor of Marine Biology and Vice President of Dalian Ocean University. Member of council of the Chinese Society of Malacology, fellow of the Chinese Society for Oceanology and Limnology. Editorial Board Member of Fish & Shellfish Immnology, Developmental and Comparative Immunology, Scientific Report.
Hannes Stockinger
Head of the Center for Pathophysiology, Infectiology and Immunology at the Medical University of Vienna and Chairman of one of the Center’s subunit, the Institute for Hygiene and Applied Immunology, where he is appointed as a full professor for molecular immunology. Further, current Chairman of the Federation of Austrian Scientific Societies. Served as officer for many other national and international scientific organizations and societies. For instance, long-lasting Treasurer of the European Federation of Immunological Societies (EFIS, 2006-2015), President of the Austrian Society for Allergology and Immunology (2000-2006), Board Member of the Austrian Science Fund (2005-2014). Identified and developed targets for diagnosis and therapeutic treatment of immunological and inflammatory diseases particularly on T cells and myeloid cells by monoclonal antibodies. The latter have been distributed to the community and used by health care centers, doctors and researchers for the diagnosis and therapy of immunological diseases and leukemias already for decades. The contribution to the understanding of how GPI-anchored receptor proteins transduce signals across the plasma membrane were fundamental for the identification and characterization of lipid rafts, membrane devices that are now recognized to control signaling across the plasma membrane. Published more than 180 papers with an h-factor of 47.
Ravi Tandon
I completed my Ph.D dissertation at the University of Zurich, Switzerland where the major focus of my PhD research project was the study of endogenous feline leukemia virus (enFeLV) in cats during exogenous feline leukemia virus (FeLV) infection. My interest in retroviruses led me into the HIV research after Ph.D. My postdoctoral research project at University of California, San Francisco was on HIV immunology. On completion of my Post Doc, I joined Dr Ndhlovu’s new laboratory at the University of Hawaii to pursue studies on HIV and Aging based on my expertise and experience to address a new area of HIV research in which have interest.
Currently my research work as an Assistant Professor at JNU, New Delhi, India is focused on aging in HIV-1-infected people. Approximately one in five individuals living with HIV infection in the United States is 50 years of age or older. This proportion continues to increase as HIV incidence remains stable and potent antiretroviral therapy has reduced the morbidity and mortality associated with HIV infection. However, premature aging and non-AIDS related morbidity including cancer seem to be a new big problem in HAART era. Chronic inflammation in treated HIV-1-infected subjects seems to play an important role in non-AIDS –related complications. The main goal of my research is to investigate the mechanism of HIV mediated accelerated aging/inflammation in HAART-suppressed HIV-1 infected people.
Ralph A Tripp
Dr. Tripp joined the University of Georgia in 2004 from the Centers of Disease Control and Prevention (CDC) in Atlanta. He is a Professor and Georgia Research Alliance Eminent Scholar working in vaccine and therapeutic studies in the Department of Infectious Diseases at UGA.
Research interests include understanding the mechanisms of immunity and disease pathogenesis associated with respiratory virus infection, and using this information to develop therapeutic protocols and vaccines that will confer long-term protective immunity.
Abhishek Tyagi
I have been working on the molecular mechanisms of cancer progression and metastasis for the last ten years, identifying signaling pathways that promote cancer progression using various in vitro and in vivo models. During this time, I have published 30 articles with more than 2000 citations, and 12 papers have been cited as being in the top 10% of the field. They have mostly appeared in high-impact journals such as Sci. Adv., Nat. Comm., J. Exp. Med., Clinical Can. Res., Oncogene, Cancer Res., Cancer Letters. My research is primarily concerned with mechanistic and translational studies of tumor-initiating cells, the microenvironment, and non-coding RNAs in the context of cancer progression and metastasis. My long-term research goal is to conduct basic and translational research to elucidate the underlying mechanism(s) driving cancer metastasis and identify therapeutic targets, especially for highly aggressive metastatic cancers. In addition, I also serve on the editorial boards of three cancer-related journals. Before joining the department of Cancer Biology at Wake Forest University School of Medicine, I was a senior research officer (SRO) at the Delhi State Cancer Institute, India (Govt. of India).
I am or have been...
1. A self-motivated, goal-oriented cellular/molecular biologist with over 7 years of experience in oncology.
2. Substantial experience in designing and executing well-controlled in vitro and in vivo assays for preclinical drug discovery, synthetic lethal screening, biomarker identification, target validation, immunogenicity, and toxicity assessment
3. Capable of investigating signaling pathways with a variety of molecular and genetic tools
4. Enthusiastic team worker and expert in forming strategic collaborations
Tiziana Vaisitti
Dr. Vaisitti has been working in the field of CLL since she started her PhD program studying the role of CD38 in the biology and pathogenesis of CLL. She continued the training in hematology/oncology obtaining a 3-year fellowship from the Italian Association for Cancer Research (AIRC), with a project aimed at analysing and dissecting the molecular mechanisms regulating leukemic proliferation and homing. Dr. Vaisitti spent several periods in Italian and foreign laboratories as a visiting scientist including a period at Feinstein Institute for Medical Research, North Shore-Long Island Jewish (NY) and a period at the Dept. of Medical Biochemistry and Immunology, Cardiff University (UK). Recently, Dr. Vaisitti spent 2 years as a visiting fellow at the Weill Cornell Medical College, Dept. of Pathology and Laboratory Medicine (NY), to set up patient-derived xenograft models of CLL and Richter syndrome, and also investigate the functional impact of novel drugs.
In the last 5 years, Dr. Vaisitti’s research has been focused on two main topics. The first one is the functional analysis of genes found recurrently mutated in chronic lymphoproliferative syndromes. Attention has been focused on NOTCH1, SF3B1, BIRC3 and NOTCH2. These works were done in a joint collaboration with the group of Prof. Gaidano (University of Eastern Piedmont, Italy). The second topic is the discovery and analysis of host microenvironmental conditions that favor leukemic development and progression.